876 related articles for article (PubMed ID: 24890440)
1. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
2. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.
Zoutendijk R; Reijnders JG; Zoulim F; Brown A; Mutimer DJ; Deterding K; Hofmann WP; Petersen J; Fasano M; Buti M; Berg T; Hansen BE; Sonneveld MJ; Wedemeyer H; Janssen HL;
Gut; 2013 May; 62(5):760-5. PubMed ID: 22490523
[TBL] [Abstract][Full Text] [Related]
3. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
[TBL] [Abstract][Full Text] [Related]
4. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
[TBL] [Abstract][Full Text] [Related]
5. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
[TBL] [Abstract][Full Text] [Related]
6. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
Lim YS; Han S; Heo NY; Shim JH; Lee HC; Suh DJ
Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062
[TBL] [Abstract][Full Text] [Related]
7. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
8. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
Elefsiniotis I; Buti M; Jardi R; Vezali E; Esteban R
Eur J Intern Med; 2009 Sep; 20(5):478-81. PubMed ID: 19712848
[TBL] [Abstract][Full Text] [Related]
12. Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis.
Shin SK; Yim HJ; Kim JH; Lee CU; Yeon JE; Suh SJ; Jung YK; Kim YS; Kim JH; Kwon OS
Gut Liver; 2021 May; 15(3):430-439. PubMed ID: 33115966
[TBL] [Abstract][Full Text] [Related]
13. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
[TBL] [Abstract][Full Text] [Related]
14. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
15. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
16. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
17. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis.
Kim EJ; Yeon JE; Kwon OS; Lee HN; Shin SK; Kang SH; Byun KS; Kim JH; Kwon SY; Suh SJ; Yim HJ; Kim YS; Kim JH
Dig Dis Sci; 2017 Mar; 62(3):808-816. PubMed ID: 28035553
[TBL] [Abstract][Full Text] [Related]
18. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
19. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
20. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
